A report by the National Academy of Sciences, Engineering, and Medicine recommends that HHS and other federal agencies form an independent organization that would rely on complex adaptive sysytems to direct cancer control in the U.S.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
